Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
First Claim
1. A method for killing target cells in a patient, wherein the target cells present a peptide consisting of the amino acid sequence of VLVPYEPPQV (SEQ ID NO:
- 77), comprising administering to the patient a composition comprising an effective number of activated T cells that selectively recognize the target cells, and wherein the target cells are cancer cells selected from the group consisting of non-small cell lung cancer, lymphoma, urinary bladder cancer, and head and neck squamous cell carcinoma, wherein the activated T cells comprise cytotoxic T cells produced by contacting T cells in vitro with an antigen presenting cell that expresses the peptide consisting of the amino acid sequence of VLVPYEPPQV (SEQ ID NO;
77) in a complex with an MHC molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
3 Citations
12 Claims
-
1. A method for killing target cells in a patient, wherein the target cells present a peptide consisting of the amino acid sequence of VLVPYEPPQV (SEQ ID NO:
- 77), comprising administering to the patient a composition comprising an effective number of activated T cells that selectively recognize the target cells, and wherein the target cells are cancer cells selected from the group consisting of non-small cell lung cancer, lymphoma, urinary bladder cancer, and head and neck squamous cell carcinoma, wherein the activated T cells comprise cytotoxic T cells produced by contacting T cells in vitro with an antigen presenting cell that expresses the peptide consisting of the amino acid sequence of VLVPYEPPQV (SEQ ID NO;
77) in a complex with an MHC molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- 77), comprising administering to the patient a composition comprising an effective number of activated T cells that selectively recognize the target cells, and wherein the target cells are cancer cells selected from the group consisting of non-small cell lung cancer, lymphoma, urinary bladder cancer, and head and neck squamous cell carcinoma, wherein the activated T cells comprise cytotoxic T cells produced by contacting T cells in vitro with an antigen presenting cell that expresses the peptide consisting of the amino acid sequence of VLVPYEPPQV (SEQ ID NO;
Specification